Nalbuphin Amomed (Nalbuphine Hydrochloride)

Nalbuphine, the active ingredient in Nalbuphin Amomed, is an opioid analgesic presented as a sterile injectable solution for intramuscular, intravenous, or subcutaneous use. It is employed to manage moderate to severe pain in various clinical settings. GNH USA supplies Nalbuphin Amomed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nalbuphine is used in the management of pain through its mixed agonist‑antagonist activity at opioid receptors.

Postoperative pain: provides analgesia for moderate to severe pain after surgery. Labor pain: used to relieve pain during childbirth. Cancer‑related pain: incorporated into multimodal regimens for severe cancer pain.

Adverse reactions may occur with nalbuphine administration.

Common Side Effects: - Dizziness - Nausea - Vomiting - Sedation

Serious or Rare Side Effects: - Respiratory depression - Hypotension - Allergic reactions, including anaphylaxis - Severe constipation or paralytic ileus

Clinicians should observe several safety considerations when using nalbuphine. - Dose adjustment in renal impairment: reduce dose and monitor renal function. - Use cautiously in hepatic impairment: monitor liver enzymes and clinical response. - Avoid in patients with known hypersensitivity to nalbuphine or its excipients. - Monitor for respiratory depression, especially when combined with other CNS depressants. - Pregnancy and lactation: safety not established; use only if benefit outweighs risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Nalbuphine may interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Concurrent use with other opioid agonists: risk of additive respiratory depression. - Combination with benzodiazepines or barbiturates: heightened CNS depression. - MAO inhibitors: may precipitate severe hypertension or serotonin syndrome.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may increase risk of urinary retention. - CYP3A4 inhibitors (e.g., ketoconazole): may raise nalbuphine plasma concentrations. - CYP3A4 inducers (e.g., rifampin): may reduce analgesic efficacy.